ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "adalimumab and methotrexate (MTX)"

  • Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting

    Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Naonobu Sugiyama 3, Noriko Iikuni 4, Koshika Soma 5, Harry Shi 6, Eduardo Mysler 7, Robert J. Moots 8, Josef Smolen 9 and Roy Fleischmann 10, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Pfizer Japan Inc, Tokyo, Japan, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 9Medical University of Vienna, Vienna, Austria, 10Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…
  • Abstract Number: 2456 • 2017 ACR/ARHP Annual Meeting

    Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)

    Arthur Kavanaugh1, Ronald F van Vollenhoven2, Prashanth Sunkureddi3, Ying Zhang4, Jessica L. Suboticki5 and Josef S. Smolen6, 1Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, 2Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 3University of Texas Medical Branch, Galveston, TX, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc., Mettawa, IL, 6Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria

    Background/Purpose : Some rheumatoid arthritis (RA) patients (pts) may experience flares in their disease even after reaching stable low disease activity (sLDA), but the consequences…
  • Abstract Number: 593 • 2016 ACR/ARHP Annual Meeting

    Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate

    Josef S. Smolen1, Ronald F. van Vollenhoven2, Benjamin A. Wolfe3, Su Chen3, Jessica L. Suboticki3 and Arthur Kavanaugh4, 1Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria, 2Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 3AbbVie Inc., North Chicago, IL, 4Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA

    Background/Purpose:  In patients (pts) with early rheumatoid arthritis (RA), conventional synthetic DMARDs (csDMARDs), preferably methotrexate (MTX), are recommended as first line therapy.1,2 For pts who…
  • Abstract Number: 640 • 2016 ACR/ARHP Annual Meeting

    Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate

    Gurjit S. Kaeley1, Veena K. Ranganath2, Daryl K. MacCarter3, Aileen L. Pangan4, Xin Wang4 and Jasmina Kalabic5, 1University of Florida, Jacksonville, FL, 2University of California at Los Angeles, Los Angeles, CA, 3North Valley Hospital, Whitefish, MT, 4AbbVie Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose:  Obese rheumatoid arthritis (RA) patients (pts) may have higher levels of inflammatory mediators, greater joint swelling and tenderness, and suboptimal response to therapy. We…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.